Hartland said "We need new info in my oplnion,we sem to be rehashing the same stuff.Am I wrong?"

You are mostly wrong, but you are also somewhat right. It's the case of something old and something new. The theme is the same, but they keep digging deeper and deeper with improved assays and technologies. Microarray data has been presented a few times before. The SOMAScan data was presented at the small NYAS meeting last month, but this will be the first large scientific meeting that it will be presented at. Plus presenting in BOTH US and Europe is important. The introduction of flavin mono-oxygenase-3 (FMO3) and its CVD-promoting product trimethylamine oxide (TMAO) is new. Also, keep in mind that abstracts 1) have space limitations and 2) must be submitted far in advance of the meeting. So you can't tell your whole story in an abstract and very likely they will be showing more data than is referred to in the abstract.

Hartland also said "There definitely has not been any positive movement from all these presentations."

I can't argue with that.

BearDownAZ